Review:clinical transfusion management in sickle cell disease by Rogers, Zora R.
126 I M M U N O H E M A T O L O G Y, V O L U M E  2 2 , N U M B E R  3 , 2 0 0 6
Sickle cell disease (SCD) is the most common
genetic disorder in the United States, affecting
individuals of sub-Saharan African, south Asian, and
Mediterranean ancestry. The abnormality is a mutation
in the sixth amino acid residue of the beta globin chain
from glutamic acid to valine (βs); resulting in a
hemoglobin tetramer that may polymerize during
normal oxygen carriage, causing the characteristic
crescent or sickle-shaped RBCs in the peripheral blood
for which the disorder is named. The abnormal RBCs
are fragile, causing chronic hemolysis that results in
anemia as well as a vasculopathy that causes ischemic
damage to many body organs, including the spleen,
kidneys, lung, and brain.
SCD includes a number of syndromes of variable
frequency and severity. Sickle cell anemia (HbSS—
homozygous for two βs genes) is the most common,
occurring in about 1 in 350 African American births.1
Symptomatic double heterozygote states for
hemoglobins that interact with βs are less common and
include sickle C disease (HbSC), and sickle beta
thalassemia (HbS-thalassemia, with the designation βo
when no hemoglobin A is produced and β+ when some
A is present). While patients with HbSS experience the
majority of the complications requiring RBC
transfusion, such conditions are all experienced albeit
less frequently by persons with other forms of SCD.
RBC transfusion, either to quickly increase the
oxygen carrying capacity from acute exacerbation of
anemia or to chronically suppress the production of βs-
containing RBCs, is a mainstay of treatment for SCD.
Although stable compensated anemia, which patients
with SCD have at baseline and during uncomplicated
acute painful crisis, does not require transfusion, the
majority of adult patients have required transfusion at
least once in their lives. This article will review the
commonly used transfusion methods, the indications
for transfusion, and the current management of iron
overload in patients with SCD.1,2
Red Blood Cell Product Selection and
Methods of Administration  
Immunologic considerations
Alloimmunization, as a result of antigenic
discrepancy between patients of African ancestry and
predominantly Caucasian blood donors,has historically
affected 5 to 50 percent of patients with SCD.
Previously undetected alloimmunization, a problem
made worse by multiple sites of care and transfusion
center ignorance of complete transfusion history, may
increase the occurrence of delayed hemolytic
transfusion reactions (DHTR). Further, the clinical
signs of DHTR may mimic those of sickle cell crisis:
pain, low-grade fever, and exaggerated anemia, so
diagnosis may be further delayed.1,2 Once such a
hemolytic reaction begins, patients with SCD may
undergo hemolysis of autologous as well as transfused
RBCs, an autohemolysis-hyperhemolysis syndrome
which may be persistent and severe.3,4 During such
events, further transfusion of even crossmatch-
compatible RBCs should be avoided, if possible. The
recommended treatment is usually corticosteroids and
intravenous gamma globulin; erythropoietin is added if
reticulocytopenia is present.1
Product selection
Because of the increased, lifelong need for RBC
transfusion as well as the increased probability and
consequences of alloantibody formation in persons
with SCD, most centers that care for a large number of
these patients perform extended RBC antigen typing
before the first transfusion. RBC components, known
to be phenotypically matched for ABO and Rh (Cc, D,
Ee) and K can then be crossmatched. Theoretical
calculations suggest that the use of a limited extended-
phenotype matching for these antigens would prevent
53 percent of antibodies in SCD patients.5 Extended-
phenotype matching for ABO, Rh, and K has been
shown in a multicenter trial to reduce the
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alloimmunization rate in patients with SCD from 3
percent to 0.5 percent per unit transfused and to
reduce DHTR by 90 percent.6 While this is
recommended, it may not be practical in all sites.1
Further, since the majority of the units will be used in
chronic transfusion programs described below, units
less than 7 to 10 days old are selected for transfusion to
SCD patients,whenever possible. Selected units should
be screened and found to be hemoglobin S (HbS)
negative.
In our center, we attempt to obtain an extended
RBC phenotype on all HbSS and HbS-βo thal patients at
a routine clinic visit before their second birthday. The
phenotype is stored in the blood center records as an
“antibody” so that when a clinical order is received for
RBCs, phenotype-matched RBCs can be provided. Our
hospital blood bank maintains an inventory of several
units of group O, D– (extended antigen phenotype
known), K– units to be used for urgent transfusion of
patients with SCD; more can be obtained from the
regional blood center within 2 to 4 hours. When an
extended phenotype has not been performed before
the request for crossmatch, the clinician is given the
option of awaiting limited antigen typing from the
regional blood center that may take 8 to 12 hours or
accepting crossmatch compatible group O,D–,K– units
already on site. For chronically transfused patients,who
use the majority of the extended-phenotyped units, the
transfusion is scheduled with the blood bank in
advance so additional units with the required
phenotype may be moved to the hospital blood
inventory the day before the planned outpatient use.
To ensure that sufficient extended-phenotype
compatible RBCs are available, our sickle cell program
has paired with the regional blood center to establish a
Special Care Team:patients volunteer to tell their stories
in donor recruitment literature branded with the logos
of the team, the hospital, and the donor center.
Volunteer donors are asked to self-identify as African
American and to indicate that they are willing to be
recalled for the program. RBC samples from identified
donors are then extended-antigen typed and thereby
linked to the program, not to a specific patient. Units
collected under this program receive a special tag at the
time of release for transfusion, raising awareness of the
need for special donors and of the program. In the first
18 months of program operation, the donor center
recorded a 3.3 percent increase in African American
donors and a 7.6 percent increase in units donated.7
Many other centers have established similar programs.
Transfusion Methods
Acute versus chronic transfusion
Acute transfusion is given for an urgent problem,
usually accelerated anemia in SCD patients, and is the
standard form of transfusion. Infusion of the bank
RBCs raises the hemoglobin and restores circulating
intravascular volume and oxygen carrying capacity.
Although blood substitutes have been tried in patients
with SCD during acute events, currently the short half-
life of such products and concerns about repeated
administration limit their usefulness.
Chronic or long-term transfusion is managed
through a program in which patients receive RBCs
every 3 to 6 weeks to suppress their own HbS
production and to ameliorate intravascular sickling and
further organ damage. Within 1 to 3 planned monthly
transfusions, the reticulocyte count is usually
suppressed to less than 5 percent, the goal being to
maintain a patient at a desired hemoglobin level and
below a specific percentage of HbS indefinitely with
continued transfusion.
Chronic transfusion—simple versus exchange
The usual volume for simple transfusion is 2 to 3
units for an adult and 10 to 15 ml/kg for a pediatric
patient, administered by peripheral or central venous
access over 4 hours. Such volumes are the easiest to
administer and reduce the concentration of HbS by
dilution. If the patient is particularly anemic (below
5–6 gm/dL) it may be possible to decrease the
percentage of HbS to below 30 percent with serial,
simple transfusions. However care must be taken to
prevent volume overload particularly if more than one
transfusion is planned in a short period of time.
Similarly, it is important to avoid a Hb of more than 11
gm/dL and its attendant hyperviscosity, which may
precipitate a painful crisis or stroke, unless the
percentage of HbS is less than 30 percent.1
Exchange transfusion can be performed manually
or by mechanical erythrocytapheresis. In acute
situations, exchange transfusion can rapidly decrease
the percentage of HbS while maintaining euvolemia
and avoiding hyperviscosity. Chronic exchange
transfusion, which usually requires two good sites of
intravenous access, can maintain the benefits of low
HbS percentage while avoiding iron overload.8 If
isovolemic hemodilution methods are used,
transfusional iron burden may even be reduced by
subsequent procedures.9
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Alternatives to Transfusion—Hydroxyurea
Hydroxyurea therapy reduces the frequency of
painful events and acute chest syndrome episodes in
patients of all ages with SCD. It also has a clear benefit
on increasing survival.10 Similar results have been seen
in pediatric patients with minimal toxicities, most
commonly reversible myelosuppression. This chemo-
therapy agent is well tolerated orally, but does require
at least monthly monitoring of the blood count and
evaluation of other potential toxicities such as
gastrointestinal upset, splenic enlargement and blood
chemistry abnormalities. This requirement for frequent
monitoring in addition to the theoretical risk of
teratogenicity and leukemogenicity have limited
hydroxyurea’s acceptance by many patients.
Indications for Transfusion
Central nervous system
1. Secondary prevention of thrombotic stroke
Acute infarctive stroke is the most common
neurologic disorder in patients with SCD, occurring in
7 to 10 percent of HbSS patients during childhood.11
These events occur as the result of a progressive
intracranial vasculopathy caused by sickle cell induced
damage to the endothelium. Chronic RBC transfusion
is the gold standard in the prevention of recurrent
events, having been reported to reduce the rate of
these events from 47 to 93 percent to 10 to 20
percent.12 However, transfusions must be continued
lifelong as discontinuation is well documented to result
in 50 percent recurrence of ischemic central nervous
system (CNS) events up to 12 years later.13 Initially the
intent is to transfuse to maintain a pretransfusion Hb of
9 to 10 gm/dL, HbS less than 30 percent, and reticu-
locyte count less than 5 percent. After four years of
continuous transfusion without recurrent neurologic
events, some centers change the pretransfusion goal to
a Hb of 8 to 8.5 gm/dL and a HbS of less than 50
percent to decrease transfused iron and lengthen the
interval between transfusions.14 Intracranial hemor-
rhage is also seen in up to 25 percent of adult patients,
but the utility of chronic transfusion in secondary
prevention of hemorrhagic stroke is less well
established.1
In a single-institution trial, Ware reported that
patients on chronic transfusion for secondary stroke
prevention can overlap treatment with concomitant
hydroxyurea therapy while gradually reducing the
intensity of transfusion and still maintain protection
again recurrent CNS events.12 Once they are stable on
hydroxyurea, phlebotomy can then be used to resolve
the transfusional iron overload. The currently enrolling
NIH-NHLBI-funded Stroke with Transfusions Changing
to Hydroxyurea (SWiTCH) study is designed to test 
this approach in a multicenter setting. At this time,
however, the use of hydroxyurea to prevent primary 
or recurrent CNS events must be considered
investigational.
2. Primary prevention of stroke
With the high-occurrence risk of stroke in children
with HbSS, a great deal of interest has been focused on
prediction of which children are at risk. Risk factors
for thrombotic stroke identified in the Cooperative
Study of Sickle Cell Disease include a prior transient
ischemic event, low steady-state Hb, elevated systolic
blood pressure as well as recent frequency of acute
chest syndrome.11 The Stroke Prevention in Sickle Cell
Anemia (STOP I) trial demonstrated that, in children
aged 2 to 16 years with a time average mean velocity of
more than 200 m/s on transcranial Doppler study,
chronic transfusion could decrease the risk of initial
stroke by 90 percent.15 In the subsequent STOP II
study, it could not be defined when it was safe to stop
transfusions, reinforcing the recommendation that they
continue indefinitely for both the primary and
secondary prevention of stroke.1
Multiorgan failure syndrome
In this life-threatening complication, which
transpires during a severe painful crisis, generalized
vaso-occlusion occurs, resulting in a rapid fall in Hb and
platelet counts, encephalopathy, and evidence of renal
and hepatic dysfunction. Prompt exchange transfusion
to a HbS less than 30 percent and a Hb of about 10
gm/dL has been associated with improved survival and
recovery of organ function.1,2
Acute chest syndrome and pulmonary hypertension
Acute chest syndrome is a unique pulmonary event
in patients with SCD defined as a new lobar or
segmental infiltrate on chest radiograph, with fever,
hypoxia, and respiratory symptoms, and is frequently
associated with an acute decline in Hb of 2 gm/dL or
more. Acute chest syndrome is the leading cause of
death of patients with SCD and recurrent events have
been implicated in the development of pulmonary
hypertension. There are no direct data that simple
transfusion can hasten the resolution of acute chest
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syndrome.1,2 Most clinicians advise simple transfusion
if there is a significant supplemental oxygen
requirement and the Hb is below 7 to 8 gm/dL.
Exchange transfusion is reserved for patients with
rapidly progressive courses, those in whom adequate
oxygenation cannot be maintained on 50 percent
supplemental oxygen, and others who might
experience dramatic improvement during the
procedure.2,9
During the STOP I trial, data accumulated that
compliance with chronic transfusion reduced the
incidence of acute chest syndrome in pediatric
patients from 15.7 to 2.2 events per 100 person years
(p=.0001).16 Clinicians will often advise a short term (6
months or less) of chronic transfusion therapy for
patients with unusually severe or frequently recurrent
acute chest syndrome. Treatment with hydroxyurea is
also appropriate, following or instead of the short 
term chronic transfusion program for prevention of
recurrent acute chest syndrome.
About one-third of adults with HbSS are reported to
have pulmonary hypertension, defined by a tricuspid
regurgitant jet velocity of equal to or more than 2.5
m/s, a diagnosis associated with premature mortality.
Chronic transfusion has also been proposed as a
treatment to stop the progression of or reverse early
pulmonary hypertension in small pilot studies.
However, the true role for chronic transfusion in
management of patients with pulmonary hypertension
may depend, as in primary stroke prevention, on
screening for early risk groups.1
Pain
There are no data that transfusion can hasten the
resolution of a painful event once it has started.
However, the STOP trial did confirm that aggressive
chronic transfusion can reduce the frequency of
painful events from 27.1 to 9.7 events per 100 patient-
years (p=.014).16 Again clinicians frequently offer a
short-term chronic transfusion program for recurrent
painful events; however hydroxyurea has also been
demonstrated to reduce the frequency of this
complication.
Exaggerated acute anemia
During the course of many complications of SCD,
patients may become more anemic than is usual for
them. RBC transfusion is indicated when there is
evidence of tissue hypoxia or end-organ stress. The
most common cause of acute anemia is transient RBC
aplasia caused by human parvovirus B19. This virus
induces RBC production arrest for 4 to 14 days, half of
the RBC life span in some forms of SCD. The Hb falls
and the reticulocyte count is usually below 1 percent.
RBC transfusion to attain a Hb of 8 to 9 gm/dL is
indicated and close follow-up required until the
reticulocyte count returns to normal.
Acute splenic sequestration and hepatic
sequestration
HbS-contained RBCs may become trapped in the
small vessels and sinusoids of the spleen and liver,
resulting in rapid organ enlargement and dysfunction.
Patients present with anemia and pain over the
enlarged organ, and thrombocytopenia is frequently
seen in severe events. Acute splenic sequestration is
most common in children with HbSS and HbS-βo thal
between 6 months and 5 years of age, where it can be
rapidly fatal if not promptly diagnosed and managed.
RBC transfusions both reverse the symptoms of acute
anemia and promote release of the sequestered cells.
Care must be exercised to prevent over-transfusion and
a rise in Hb to more than 11 gm/dL, at which point the
patient is at risk for hyperviscosity and sludging,
particularly within the intracranial vessels.
Chronic, sometimes painful, splenomegaly, which
can be seen in patients with all forms of SCD but
particularly in adolescents and young adults with
HbSC, may also be observed. This does not usually
require acute transfusion but may place the patient at
increased risk of exaggerated acute anemia during
intercurrent illness. For recurrent splenic sequestra-
tion episodes requiring transfusion, splenectomy
should be considered. A short-term chronic transfusion
program may be used to foster involution of the spleen
or temporize until the clinician or the family is
comfortable with splenectomy.
Hepatic sequestration is marked by a 3- to 4-fold
increase in transaminases and bilirubin in association
with anemia and painful hepatomegaly. Acute
transfusion is required when anemia is severe and over-
transfusion should be avoided as outlined above.
Priapism
Priapism,a prolonged painful erection of the penis,
is a very common complication of SCD,occurring most
commonly in patients with HbSS beginning at 2 to 3
years of age. Although anecdotal response to RBC
therapy has been reported, there has never been a
randomized controlled trial of simple or exchange
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transfusion in management of either prolonged or
recurrent priapism. Recent research has demonstrated
the frequent success of alternative medical and surgical
strategies to relieve the acute prolonged (more than 4-
hour) episodes of priapism that may lead to penile
ischemia, fibrosis, and impotence.17 Further, an associ-
ation between SCD, priapism, exchange transfusion,
and neurologic events dubbed the ASPEN syndrome
has been reported.18 As a result, most centers reserve
transfusion for single episodes unresponsive to
alternative management that have persisted for more
than 24 hours. Limited chronic RBC transfusion has
also been used to prevent recurrent priapism in
patients with frequently recurrent prolonged episodes.
Pregnancy
There are conflicting data regarding the benefit of
regular “chronic”transfusion during pregnancy. Instead
most centers provide selective transfusion targeted to
address clearly identifiable medical and obstetric
complications such as hypoxemia, progressive
symptomatic anemia, acute chest syndrome, splenic
sequestration, or pre-eclampsia during pregnancy.1,2
Leg ulcers
Leg ulcers occur on either side of the malleolus
spontaneously or following minor trauma, often
becoming infected, and are very slow to heal. While
higher Hb levels are thought to benefit wound healing,
there is a paucity of clinical data to support use of
chronic transfusion in SCD-related leg ulcers.1,2
Preparation for general anesthesia
The need for surgical intervention is common in
patients with SCD and general anesthesia is associated
with painful crisis, acute chest syndrome, and excess
mortality within the week. Routine preoperative and
often exchange transfusions have been the standard
practice for patients undergoing major surgery,
particularly where upper abdominal incisions may
predispose to hypoventilation,but the practice is based
on little firm data.
The preoperative transfusion study found no
difference in outcome between routine preoperative
transfusion to about 10 gm/dL by aggressive exchange
to less than 30 percent HbS and simple transfusion to
the target Hb regardless of HbS percentage. However
the simple transfusion group had the advantage of
reduced transfusion-related complications.19 In
addition, this trial was limited by enrollment of few
patients more than 21 years of age with known
cardiopulmonary dysfunction (recurrent acute chest
syndrome or pulmonary hypertension) so some
authors continue to advocate exchange transfusion for
selected high-risk patients.1 Other authors have
demonstrated that for low-risk cases transfusion is not
required.20 Thus the decision to transfuse must be
individualized. In our center, patients with SCD with a
steady-state Hb less than 8.5 gm/dL (hemoglob-
inopathies other than HbSS and HbS-βo thal), not
undergoing upper abdominal surgery (any case other
than cholecystectomy and splenectomy),and without a
history of recent or recurrent acute chest syndrome
would be less likely to require preoperative
transfusion.
Iron overload
The obligate burden of recurrent acute or chronic
transfusion is iron overload. Before 2006, iron over-
load necessitated chelation with subcutaneous or
intravenous deferoxamine (Desferal, Novartis
Pharmaceuticals Corp., East Hanover, NJ). The rigorous
demands of subcutaneous deferoxamine infusion,10 to
12 hours a night, 5 or 6 nights a week, invited poor
adherence, leaving patients protected from the compli-
cations of SCD but at risk for hepatic and cardiac
damage from the transfused iron.
The oral iron-chelator deferasirox (Exjade, Novartis
Pharmaceuticals Corp.) was just licensed in the United
States for treatment of transfusional hemosiderosis in
patients 2 years of age and older. This oral dispersible
tablet is taken on an empty stomach 30 minutes before
eating daily and causes chelated iron to be excreted in
the stool. In head-to-head studies iron excretion
equivalent to the iron removed with deferoxamine was
observed. Deferasirox has a significant side effect
profile with pruritic rash, abdominal pain, and
elevations in both creatinine and transaminases being
seen in 6 to 38 percent of patients. Most toxicities
respond to suspension of the medication and
reintroduction at a lower dose.21 While there are other
oral iron-chelators in advanced clinical trials,
deferasirox is the only one approved for use in the
United States.
The availability of this oral iron-chelator will likely
increase the willingness of clinicians to use RBC
transfusion therapy. However, the efficacy of this
medication to remove all concerns of iron overload
from patients with SCD who require chronic or
repetitive transfusion has not yet been demonstrated
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and given the significant side effects observed in the
licensure trials and in early clinical use, significant
concerns still exist.
References
1. Wanko SO, Telen MJ. Transfusion management in
sickle cell disease. Hematol Oncol Clin N Am
2005;19:803-26.
2. Rosse WF,Telen MJ,Ware RE. Transfusion support
for patients with sickle cell disease. Bethesda, MD,
AABB Press: 1998.
3. Triluzi DJ. Blood transfusion therapy:a physician’s
handbook. 7th ed. Bethesda MD, AABB Press:
2002;111-6.
4. Talano JA, Hillery CA, Gottsschall JL, et al. Delayed
hemolytic transfusion reaction/hyperhemolysis
syndrome in children with sickle cell disease.
Pediatrics  2003;111:661-5.
5. Castro O, Sandler SG, Houston-Yu P, Rana S.
Predicting the effect of transfusing only pheno-
type matched RBC’s to patients with sickle cell
disease: theoretical and practical implications.
Transfusion 2002;42:684-91.
6. Vichinsky  EP, Luban NL,Wright E, et al. Prospec-
tive red blood cell phenotype matching in a
stroke-prevention trial in sickle cell anemia: a
multicenter transfusion trial. Transfusion 2001;
41:1086-92.
7. Nizzi F. Medical Director, Carter BloodCare at
Childrens. Personal communication. 2004.
8. Kim HC, Dugan NP, Silber JH, et al.
Erythrocytapheresis therapy to reduce iron
overload in chronically transfused patients with
sickle cell disease. Blood 1994;83:1136-42.
9. Bruce C. McLeod, editor. Therapeutic apheresis: a
physicians handbook. 1st ed. Bethesda MD, AABB
Press: 2005;120-7,146-50.
10. Steinberg MH, Barton F, Castro O, et al. Effect of
hydroxyurea on mortality and morbidity in adult
sickle cell anemia: risks and benefits up to 9 years
of treatment. JAMA 2003; 289:1645-51.
11. Ohene-Frempong K, Weiner SJ, Sleeper, LA, et al.
Cerebrovascular accidents in sickle cell disease:
rates and risk factors. Blood 1998;91:288-94.
12. Ware RE, Zimmerman SA, Sylvestre PB, et al.
Prevention of secondary stroke and resolution of
transfusional iron overload in children with sickle
cell anemia using hydroxyurea and phlebotomy.
J Pediatr 2004;145:346-52.
13. Wang WC, Kovnar EH,Tonkin IL, et al. High risk of
recurrent stroke after discontinuance of five to
twelve years of transfusion therapy in patients
with sickle cell disease. J Pediatr 1991;118:
377-82.
14. Cohen AR, Martin MB, Silber JH et al. A modified
transfusion program for prevention of stroke in
sickle cell disease. Blood 1992;79:1657-61.
15. Adams RJ, McKie VC, Hsu L et al. Prevention of a
first stroke by transfusions in children with sickle-
cell anemia and abnormal results on transcranial
Doppler ultrasonography. N Engl J Med 1998;339:
5-11.
16. Miller St, Wright E, Abboud M, et al. Impact of
chronic transfusion on incidence of pain and
acute chest syndrome during the Stroke
Prevention Trial (STOP) in sickle-cell anemia. J
Pediatr 2001;139:785-9.
17. Mantadakis E, Ewalt DH, Cavender JD, et al.
Outpatient penile aspiration and epinephrine
irrigation for young patients with sickle cell
anemia and prolonged priapism. Blood 2000;
95:78-82.
18. Siegel JF, Rich MA, Brock WA.Association of sickle
cell disease, priapism, exchange transfusion and
neurological events: Aspen syndrome. J Urol
1993;150:1480-2.
19. Vichinsky EP, Haberkern CM, Neumayr L, et al. A
comparison of conservative and aggressive
transfusion regimens in the perioperative
management of sickle cell disease. N Engl J Med
1995;333:206-13.
20. Fu T, Corrigan NJ, Quinn CT, Rogers ZR, Buchanan
GR. Minor elective surgical procedures using
general anesthesia in children with sickle cell
anemia without pre-operative blood transfusion.
Pediatr Blood Cancer 2005;45:43-7.
21. Package insert: Exjade (deferasirox). Novartis
Pharmaceuticals Corporation, East Hanover, New
Jersey. November 2005.
Zora R.Rogers, M.D., Associate Professor of Pediatrics,
UT Southwestern, Director of the Clinical Core, NIH-
NHLBI Southwestern Comprehensive Sickle Cell
Center, 5323 Harry Hines Boulevard, Dallas, Texas
75390-9063.
